- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06688058
Ett försök för att utvärdera tolerabilitet och immunogenicitet hos V540D hos friska vuxna (V540D-004)
En fas 1, randomiserad, dubbelblind, komparatorkontrollerad, dosökningsstudie för att utvärdera, tolererbarhet och immunogenicitet hos V540D hos friska vuxna.
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later.
A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other types of HPV. The study vaccine (called V540D) is designed to protect against the same HPV types that G9 protects against plus other HPV types. The main goal of this study is to learn about the safety of V540D in healthy adults and if people tolerate it.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Florida
-
Hollywood, Florida, Förenta staterna, 33024
- Research Centers of America ( Hollywood ) ( Site 0001)
-
-
Georgia
-
Savannah, Georgia, Förenta staterna, 31406
- Velocity Clinical Research, Savannah ( Site 0005)
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64114
- Alliance for Multispecialty Research, LLC ( Site 0003)
-
-
Tennessee
-
Knoxville, Tennessee, Förenta staterna, 37920
- Alliance for Multispecialty Research, LLC ( Site 0004)
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
The key inclusion criteria include but are not limited to the following:
- Is in good health based on medical history, physical examination, vital sign (VS) measurements and electrocardiograms (ECGs) performed before randomization
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
- Has a history of abnormal Pap smears, HPV- related external genital lesions (eg, condyloma acuminate, vulval intraepithelial neoplasia (VIN), or prostatic intraepithelial neoplasia (PIN)) or external genital cancer (eg, penile cancer), HPV-related vaginal or anal lesions (eg, condyloma acuminata or vaginal intraepithelial neoplasia (VaIN)) or vaginal or anal cancer
- Has a history of cancer (malignancy)
- Has received any HPV vaccine or is expected to receive any HPV vaccine during the study, outside the protocol
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: V540D
Participants will receive vaccinations with V540D. |
Experimental vaccine and adjuvant administered via intramuscular (IM) injection |
|
Aktiv komparator: GARDASIL®9
Participants will receive vaccinations with GARDASIL®9. |
Suspension administered via IM injection
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE)
Tidsram: Up to approximately 6 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
Up to approximately 6 months
|
|
Number of Participants Who Experience a Solicited Systemic AE
Tidsram: Up to approximately 6 months
|
Solicited systemic AEs include headache, fatigue, nausea, dizziness, muscle aches, joint pain. |
Up to approximately 6 months
|
|
Number of Participants Who Experience Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
Tidsram: Up to approximately 6 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
Up to approximately 6 months
|
|
Number of Participants Who Experience Unsolicited AEs
Tidsram: Up to approximately 7 months
|
An unsolicited AE is an event that is not predefined as a solicited AE or is predefined as a solicited AE but reported at any time outside the solicited time period. |
Up to approximately 7 months
|
|
Number of Participants Who Experience a Serious Adverse Event (SAE)
Tidsram: Up to approximately 18 months
|
SAEs include AEs that result in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. |
Up to approximately 18 months
|
|
Number of Participants Who Experience a Medically-Attended AE (MAAE)
Tidsram: Up to approximately 18 months
|
AEs in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. Routine visits are not considered MAAEs. Examples of routine visits include physical examination, wellness visits, or vaccinations. |
Up to approximately 18 months
|
|
Number of Participants Who Experience an Event of Clinical Interest (ECI)
Tidsram: Up to approximately 18 months
|
ECIs are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs). |
Up to approximately 18 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Total Immunoglobulin G (IgG) Geometric Mean Ratios (GMRs) for anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Tidsram: Up to approximately 7 months
|
GMR of titers for participants vaccinated with V540D versus those who received GARDASIL®9 alone will be calculated. |
Up to approximately 7 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Medical Director, Merck Sharp & Dohme LLC
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- V540D-004
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .